

**BME - GROWTH**

Palacio de la Bolsa  
Plaza de la Lealtad, 1  
28014 Madrid

Alicante, October 4<sup>th</sup>, 2024

**COMMUNICATION- PRIVILEGED INFORMATION- FACEPHI BIOMETRIA, S.A.**

Dear Sirs,

Under the provisions of Article 17 of Regulation (EU) No. 596/2014 on market abuse, and Article 228 of Law 6/2023, dated March 17<sup>th</sup>, of the Spanish Securities Market and Investment Services, along with related provisions, as well as in Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter "Facephi" or "the Company", interchangeably).

Facephi and Nice & Green, the main shareholder of the Company, signed on October 1<sup>st</sup>, 2024, a new loan for the amount of € 2,000,000.

The terms and conditions of the loan are as follows:

- The maturity date of the loan is March 31<sup>st</sup>, 2025. The loan may be repaid in cash or capitalized. In the case of capitalization (i.e., conversion of the loan into shares of the Company), the parties will enter into a new agreement establishing the exchange ratio.
- The loan will bear annual interest at Euribor plus 2%, payable at maturity. In addition to the principal, the parties may agree that accrued interest will be capitalized and added to the principal balance.
- The loan has a loan origination fee of 7%.

Javier Mira, Chairman of the Board of Directors, declares: *"This new financing agreement is consistent with the decision announced on May 13<sup>th</sup>, 2024, not to pursue the issuance of additional convertible bonds in our association with Nice & Green, Facephi's main shareholder, in order to maintain a stable and homogeneous shareholding structure. By avoiding the use of convertible instruments that could dilute shareholder participation, we prioritize financing alternatives that do not affect the interests of existing shareholders, thus ensuring a productive and successful long-term relationship with all our stakeholders."*

In compliance with the provisions of Circular 3/2020 of the BME Growth segment of BME MTF Equity, it is expressly stated that the information hereby communicated has been prepared under the sole responsibility of the Company and its directors.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

---

Javier Mira Miró  
**Chairman of the Board of Directors**